Sotuvning sof marjinal rentabelligi: sunshinebiopharma.com (SBFM)

Sunshine Biopharma (SBFM) korporativ emblemasi va logotipi

Sunshine Biopharma (SBFM) global reagent yetkazib berishdagi uzilishlarga va dori vositalarini ro'yxatdan o'tkazish davridagi geosiyosiy to'siqlarga moyil hisoblanadi. Kompaniyaning savdo marjalari joriy operatsion barqarorlikni namoyish etmoqda, bunda parametr -17.40 ga tengdir. O'simta qarshiligiga qarshi kurashish uchun kichik molekulali platformaning ishlab chiqilishi noyob qiymat yaratadi, garchi likvidlik yetishmovchiligi va tadqiqotlarning erta bosqichidagi xatarlar aksiyalar ulushining kamayishiga olib kelishi mumkin bo'lsa-da.

Sunshine Biopharma, Inc. (SBFM) - Kompaniya sotuv marjasi 04.07.2022dan 19.11.2026gacha

Sunshine Biopharma kompaniyasining tahliliy kesimlari

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Kompaniyaning jamlanma tahliliyoti:Sunshine Biopharma, Inc. - SBFM
Sunshine Biopharma Inc. yetakchi tovari

Sof foyda marjasi barcha operatsion va moliyaviy majburiyatlar qoplanilgandan so'ng biznesda qolgan foyda qismini aks ettiradi. Ushbu ko'rsatkich ichki xarajatlarga qarshi kapital barqarorligini stress-test qilish vositasi bo'lib xizmat qiladi. Sotuv marjasining joriy -17.40 darajasi Sunshine Biopharma kompaniyasining tashqi moliyalashtirishga bo'lgan kritik bog'liqligini aks ettiradi. Narxlarni belgilash imkoniyatining yo'qligi va shaxsiy daromad manbalarining mavjud emasligi ushbu ko'rsatkichni salbiy qiladi. Investorlar bunday qiymatlarni klinik biotexnologiya sohasiga xos bo'lgan ventura risklarining ko'rsatkichi sifatida talqin qilishlari kerak.

Toʻgʻridan-toʻgʻri raqobatchilar

ONC: Sotuvning sof marjinal rentabelligi|Sof marja Halozyme Inc. (HALO)|Sof marja RevMed|Sotuvning sof rentabelligi AAPG (Ascentage Pharma Group)|Sotuvning sof marjinal rentabelligi CGON|UroGen Pharma - Sotuvning sof rentabelligi|Bicara Therapeutics - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof marjinal rentabelligi Personalis Inc PSNL|Erasca Oncology - Sotuvning sof marjinal rentabelligi|Sof foyda normasi DCTH (Delcath Corp)|YMAB: Sotuvning sof marjinal rentabelligi|AURA - Kompaniya sotuv marjasi|CADL (Candel Therapeutics Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi ARAY (Accuray)|Sof foyda bo'yicha sotuv rentabelligi SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Sof marja|Sof marja Citius Oncology, Inc. CTOR|HURA - Sof foyda bo'yicha sotuv rentabelligi|protaratx.com - Sotuvning sof marjinal rentabelligi|FATE - Sotuvning sof marjinal rentabelligi|WHWK: Sotuvning sof marjinal rentabelligi|TScan Therapeutics (TCRX) - Sotuvning sof marjinal rentabelligi|Sof marja Champions Oncology|Sof marja XBIT|Sotuvning sof marjinal rentabelligi CVM|Sof foyda bo'yicha sotuv rentabelligi OS Therapies Inc. OSTX|Sof marja Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Sof marja|ANL - Sof marja|Sof marja verupharma.com|TPST: Sotuvning sof marjinal rentabelligi|XLO - Kompaniya sotuv marjasi|Sof marja Renovaro|Sotuvning sof marjinal rentabelligi muraloncology.com|Sotuvning sof marjinal rentabelligi KAPA|Kompaniya sotuv marjasi OnKure Therapeutics, Inc.|Sotuvning sof marjinal rentabelligi GDTC (w2.cytomed.sg)|CRIS - Sof foyda bo'yicha sotuv rentabelligi|Apollomics - Sotuvning sof marjinal rentabelligi|Tharimmune Corp (THAR) - Sof foyda bo'yicha sotuv rentabelligi|ADVB: Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha sotuv rentabelligi Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof marjinal rentabelligi xeneticbio.com|Sof marja Salarius (SLRX)|Sof foyda bo'yicha sotuv rentabelligi Purple Biotech PPBT|Sof marja American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Sof marja|Checkpoint Therapeutics Inc. - Sotuvning sof marjinal rentabelligi|Sof foyda normasi ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Sof foyda bo'yicha sotuv rentabelligi|Ikena Oncology, Inc. - Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi NTBL|VIRX: Sof foyda normasi|Sof marja MorphoSys Corporation (MOR)|NAYA - Sof marja|Sotuvning sof marjinal rentabelligi AAPGV (Ascentage)